RxDoctor Payments Data

Shaheen Ali, MD

Internal Medicine · Reno, NVNPI 1992777478

Payments from drug & device makers

$1,108in general payments, 2019–2025

Across 68 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$467
  • GSK$213
  • AstraZeneca$180
  • Amgen$93
  • Lilly USA, LLC$45
  • Idorsia Pharmaceuticals US Inc$36
  • plus $74 from 5 others

What the payments were for

  • Food & beverage$1,108100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,108 in reported general payments places this provider in the 75th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$437,977
Medicare patients
440
Services billed
4,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$108,412
TrulicityDulaglutide53$95,875
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$93,686
EliquisApixaban45$66,776
JardianceEmpagliflozin31$44,087
Breo ElliptaFluticasone/Vilanterol41$39,391
XareltoRivaroxaban20$32,938
ProliaDenosumab17$28,908
SynthroidLevothyroxine Sodium133$14,766
Repatha SureclickEvolocumab13$13,215
Rosuvastatin Calcium298$5,493
Omeprazole271$4,933
Losartan Potassium287$3,325
Atorvastatin Calcium262$3,155
Levothyroxine Sodium255$2,979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$213$133,077117 claims
Lilly USA, LLCTrulicity$45$95,87553 claims
AmgenProlia$93$28,90817 claims
AbbVieSynthroid, Armour Thyroid$467$17,714173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →